{"transactions":[{"id":3188813,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-04-01T16:11:24.000Z","date":"2020-04-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in four equal installments on June 30, 2020, September 30, 2020, December 31, 2020 and March 31, 2021."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001618835-20-000073","document":"wf-form4_158577186560857.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883520000073/wf-form4_158577186560857.xml","form_type":"4"}},{"id":3188812,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-04-01T16:11:24.000Z","date":"2020-03-31","kind":"exercise","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001618835-20-000073","document":"wf-form4_158577186560857.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883520000073/wf-form4_158577186560857.xml","form_type":"4"}},{"id":3188811,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T16:11:24.000Z","date":"2020-03-31","kind":"exercise","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."}],"balance_after":325000,"source":{"system":"sec-edgar","filing":"0001618835-20-000073","document":"wf-form4_158577186560857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883520000073/wf-form4_158577186560857.xml","form_type":"4"}},{"id":3328784,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-12-31T20:48:42.000Z","date":"2019-12-31","kind":"exercise","acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."}],"balance_after":37500,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001618835-19-000219","document":"wf-form4_157784330245840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883519000219/wf-form4_157784330245840.xml","form_type":"4"}},{"id":3328783,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-31T20:48:42.000Z","date":"2019-12-31","kind":"exercise","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."}],"balance_after":287500,"source":{"system":"sec-edgar","filing":"0001618835-19-000219","document":"wf-form4_157784330245840.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883519000219/wf-form4_157784330245840.xml","form_type":"4"}},{"id":3402683,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-10-01T11:55:47.000Z","date":"2019-09-30","kind":"exercise","acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001628280-19-012045","document":"wf-form4_156994532484636.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000162828019012045/wf-form4_156994532484636.xml","form_type":"4"}},{"id":3402682,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-10-01T11:55:47.000Z","date":"2019-09-30","kind":"exercise","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."}],"balance_after":250000,"source":{"system":"sec-edgar","filing":"0001628280-19-012045","document":"wf-form4_156994532484636.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000162828019012045/wf-form4_156994532484636.xml","form_type":"4"}},{"id":3474444,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-07-01T14:42:35.000Z","date":"2019-06-30","kind":"exercise","acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."}],"balance_after":112500,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001618835-19-000138","document":"wf-form4_156200652729907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883519000138/wf-form4_156200652729907.xml","form_type":"4"}},{"id":3474443,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-01T14:42:35.000Z","date":"2019-06-30","kind":"exercise","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."}],"balance_after":212500,"source":{"system":"sec-edgar","filing":"0001618835-19-000138","document":"wf-form4_156200652729907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883519000138/wf-form4_156200652729907.xml","form_type":"4"}},{"id":3564026,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-04-03T18:40:51.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services to be provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer effective April 1, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units shall vest in four equal installments on June 30, 2019, September 30, 2019, December 31, 2019 and March 31, 2020."}],"balance_after":150000,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001618835-19-000047","document":"wf-form4_155433123601709.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883519000047/wf-form4_155433123601709.xml","form_type":"4"}},{"id":3611682,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:04:08.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006328/doc4.xml","form_type":"4"}},{"id":3611681,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:04:08.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2021-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006328/doc4.xml","form_type":"4"}},{"id":3611680,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:04:08.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":3144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019."}],"balance_after":3144,"derivative":{"exercise_price":0.0013,"exercise_date":"2020-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":3144},"source":{"system":"sec-edgar","filing":"0000899243-19-006328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006328/doc4.xml","form_type":"4"}},{"id":3611679,"issuer":{"id":139616,"kind":"organization","name":"GW PHARMACEUTICALS PLC","symbol":"GWPH"},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-03-05T21:04:08.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":16548,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted pursuant to the Issuer's Long-Term Incentive Plan."},{"field":"security","element":"securityTitle","label":"F2","text":"The reported options are options to purchase American Depositary Shares of the Issuer (\"ADS\"). Each ADS represents twelve ordinary shares of the Issuer."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price reported is price per ordinary share converted from price per ADS ($172.01)."}],"balance_after":16548,"derivative":{"exercise_price":14.33,"exercise_date":"2022-03-01","expiration_date":"2029-03-01","underlying":"Ordinary Shares","underlying_shares":16548},"source":{"system":"sec-edgar","filing":"0000899243-19-006328","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1351288/000089924319006328/doc4.xml","form_type":"4"}},{"id":3843087,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-15T19:09:43.000Z","date":"2018-08-15","kind":"purchase","acquired":true,"shares":68929,"price":2.33,"value":160604.57,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.25 to $2.39, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":175000,"source":{"system":"sec-edgar","filing":"0001618835-18-000086","document":"wf-form4_153437456647358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000086/wf-form4_153437456647358.xml","form_type":"4"}},{"id":3843086,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-15T19:09:43.000Z","date":"2018-08-14","kind":"purchase","acquired":true,"shares":31071,"price":2.1,"value":65249.1,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.098 to $2.10, inclusive. The reporting person undertakes to provide to Evofem Biosciences, Inc. (Evofem), any security holder of Evofem, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":106071,"source":{"system":"sec-edgar","filing":"0001618835-18-000086","document":"wf-form4_153437456647358.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000086/wf-form4_153437456647358.xml","form_type":"4"}},{"id":3854775,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-08-02T16:22:01.000Z","date":"2018-07-31","kind":"grant","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. The option was awarded in connection with Mr. Lynch's consulting services."}],"balance_after":85500,"derivative":{"exercise_price":2.1,"expiration_date":"2028-07-31","underlying":"Common Stock","underlying_shares":85500},"source":{"system":"sec-edgar","filing":"0001618835-18-000076","document":"wf-form4_153324130486945.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000076/wf-form4_153324130486945.xml","form_type":"4"}},{"id":3874253,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-07-03T16:56:04.000Z","date":"2018-07-02","kind":"exercise","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on July 2, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on July 2, 2018."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001618835-18-000046","document":"wf-form4_153065134806235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000046/wf-form4_153065134806235.xml","form_type":"4"}},{"id":3874252,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-07-03T16:56:04.000Z","date":"2018-07-02","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on July 2, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on July 2, 2018."}],"balance_after":75000,"derivative":{"underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001618835-18-000046","document":"wf-form4_153065134806235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000046/wf-form4_153065134806235.xml","form_type":"4"}},{"id":3874251,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-03T16:56:04.000Z","date":"2018-07-02","kind":"exercise","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units were granted in consideration for certain consulting services provided to the Issuer in connection with the consulting agreement between Mr. Lynch and the Issuer dated April 1, 2016."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001618835-18-000046","document":"wf-form4_153065134806235.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000046/wf-form4_153065134806235.xml","form_type":"4"}},{"id":3940644,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-05-09T18:35:03.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":12875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock exercisable pursuant to the option will vest in full upon completion of continuous service for the Issuer on the first anniversary of the vesting commencement date of May 8, 2018. The option was awarded in connection with Mr. Lynch's board and committee services."}],"balance_after":12875,"derivative":{"exercise_price":6.99,"expiration_date":"2028-05-08","underlying":"Common Stock","underlying_shares":12875},"source":{"system":"sec-edgar","filing":"0001618835-18-000018","document":"wf-form4_152590524333829.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000161883518000018/wf-form4_152590524333829.xml","form_type":"4"}},{"id":3996031,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-03-14T18:17:43.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Mr. Lynch acquired a vested interest in one hundred twenty-five thousand (125,000) shares of common stock exercisable pursuant to the option effective as of March 12, 2018. The remaining shares shall vest in a series of twelve (12) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from April 1, 2018. The option was awarded in connection with Mr. Lynch's consulting services provided to the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":7.29,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001209191-18-019671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000120919118019671/doc4.xml","form_type":"4"}},{"id":3996030,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-03-14T18:17:43.000Z","date":"2018-03-12","kind":"grant","acquired":true,"shares":24691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from March 12, 2018. The option was awarded in connection with Mr. Lynch's board services."}],"balance_after":24691,"derivative":{"exercise_price":7.29,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":24691},"source":{"system":"sec-edgar","filing":"0001209191-18-019671","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000120919118019671/doc4.xml","form_type":"4"}},{"id":4095798,"issuer":{"id":8607,"kind":"organization","name":"Evofem Biosciences, Inc."},"owners":[{"id":150162,"kind":"person","name":"Lynch Thomas G","position":1,"cik":"0001360000","reported_name":"Lynch Thomas G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-18T17:05:39.000Z","date":"2018-01-17","kind":"grant","acquired":true,"shares":3850,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 17, 2018, Issuer completed a merger transaction (the \"Merger\") pursuant to an Agreement and Plan of Merger and Reorganization, dated October 17, 2017, by and among Issuer, Nobelli Merger Sub, Inc., and Evofem Biosciences Operations, Inc., formerly known as Evofem Biosciences, Inc. (\"Evofem Operations\"), as filed with the Securities and Exchange Commission on Form 8-K on October 17, 2017 (the \"Merger Agreement\"). Pursuant to the Merger Agreement all issued and outstanding options of Evofem Operations converted into and became options to purchase shares of Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These options to purchase common stock of Issuer were received in connection with the Merger in exchange for options to purchase shares of common stock of Evofem Operations. Each option to purchase one share of common stock of Evofem Operations was cancelled and exchanged for the right to receive an option to purchase 0.154 shares of common stock of Issuer. The shares of common stock of Issuer exercisable pursuant to the option reported reflect any necessary adjustments to account for the 6 for 1 reverse stock split effected by Issuer on January 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Mr. Lynch's interest in the shares of common stock exercisable pursuant to the option effective as of October 13, 2016 vested in a series of twenty-four (24) successive equal monthly installments commencing on April 1, 2016, such that all shares of common stock of Issuer exercisable pursuant to the option were fully vested as of March 1, 2017."}],"balance_after":3850,"derivative":{"exercise_price":46.36,"expiration_date":"2026-10-13","underlying":"Common Stock","underlying_shares":3850},"source":{"system":"sec-edgar","filing":"0001209191-18-004303","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1360000/000120919118004303/doc4.xml","form_type":"4"}}]}